Nektar Bolsters Finances, Advances Treg Therapy Pipeline
Event summary
- Nektar Therapeutics concluded a secondary offering in February 2026, raising $460 million in gross proceeds and an additional $44 million through an ATM offering.
- The company's 2025 revenue decreased to $55.2 million from $98.4 million in 2024, primarily due to the sale of the Huntsville manufacturing facility and decreased royalty revenue.
- Rezpegaldesleukin (REZPEG) Phase 2b data demonstrated durable responses in atopic dermatitis and alopecia areata, suggesting potential for complete disease clearance with maintenance dosing.
- Nektar plans to initiate Phase 3 trials for rezpegaldesleukin in atopic dermatitis in June 2026.
The big picture
Nektar's recent financing and promising Phase 2 data for rezpegaldesleukin represent a significant inflection point for the company, positioning it to compete in the rapidly growing immunology market. The sale of the Huntsville facility signals a shift towards a more asset-light model, focusing on clinical development and strategic partnerships. However, the company's revenue decline underscores the challenges of transitioning to a fully clinical-stage biotech.
What we're watching
- Clinical Execution
- The success of the upcoming Phase 3 trial for atopic dermatitis will be critical in validating rezpegaldesleukin's efficacy and driving future valuation, and the timeline for data readouts will be closely monitored.
- Financial Runway
- While the recent financing provides substantial runway, Nektar's ability to manage operating expenses and avoid further dilution will be essential for long-term sustainability.
- Pipeline Diversification
- The progress of Nektar's TNFR2 agonist antibody and bispecific programs, NKTR-0165 and NKTR-0166, will be important to observe as a potential source of future revenue and diversification beyond rezpegaldesleukin.
Related topics